Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

< Back to Article

Initial dose reduction of enzalutamide does not decrease the incidence of adverse events in castration-resistant prostate cancer

Table 5

Any grade of adverse events (AE) based on initial dose of enzalutamide.

Table 5

doi: https://doi.org/10.1371/journal.pone.0258160.t005